Avances en investigación de la discapacidad intelectual de origen genético: tratamientos experimentales en el síndrome X frágil

Yolanda de Diego Otero, Lucía Pérez Costillas, Rocío Calvo Medina, Carolina Quintero Navarro, Isabel del Pino Benítez, Yolanda Casado Martín, Cristina Nogueira Cobas

Resumen


De Diego Otero, Y. et al. (2017): “Avances en investigación de la discapacidad intelectual de origen genético: tratamientos experimentales en el síndrome X frágil”. Revista Española de Discapacidad, 5 (I): 217-227.


Palabras clave


Síndrome X frágil, estrés oxidativo, vitaminas, antioxidantes, ensayo clínico, comportamiento.

Texto completo:

PDF

Referencias


Bechara, E. G. et al. (2009): “A novel function for fragile X mental retardation protein in translational activation”. PLoS Biol, 7 (1): e16.

Berry-Kravis, E. y Potanos, K. (2004): “Psychopharmacology in fragile X syndrome— present and future”. Ment Retard Dev Disabil Res Rev, 10 (1): 42-48.

Bourgeois, J. A. et al. (2009): “A review of fragile X premutation disorders: expanding the psychiatric perspective”. J Clin Psychiatry, 70 (6): 852-862.

Brown, V. et al. (2001): “Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome”. Cell, 107 (4): 477-487.

Chen, L. et al. (2003): “The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences”. Neuroscience, 120 (4): 1005-1017.

Chiurazzi, P. et al. (2003): “Understanding the biological underpinnings of fragile X syndrome”. Curr Opin Pediatr, 15 (6): 559-566.

Chiurazzi, P. et al. (1999): “Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene”. Hum Mol Genet, 8 (12): 2317-2323.

Davidovic, L. et al. (2011): “A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model”. Genome Res, 21 (12): 2190-2202.

De Diego Otero, Y. et al. (2014): “A combination of ascorbic acid and a-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial”. Trials, 15: 345.

De Diego Otero, Y. et al. (2009): “Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency”. Neuropsychopharmacology, 34 (4): 1011-1026.

Dyer-Friedman, J. et al. (2002): “Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome”. J Am Acad Child Adolesc Psychiatry, 41 (3): 237-244.

El Bekay, R. et al. (2007): “Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome”. Eur J Neurosci, 26 (11): 3169-3180.

Fernandez-Carvajal, I. et al. (2009): “Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population”. J Mol Diagn, 11 (4): 324-329.

Fisch, G. S. et al. (1988): “Folic acid treatment of fragile X males: a further study”. Am J Med Genet, 30 (1-2): 393-399.

Fung, L. K. y Reiss, A. L. (2016): “Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome”. Biol Psychiatry, 80 (2): 100-111.

Gatto, C. L. y Broadie, K. (2010): “Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models”. Front Synaptic Neurosci, 2: 4.

Gomis-González, M. et al. (2016): “Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key. Alterations in Fragile X Syndrome Mouse Model”. Genes (Basel), 7 (9).

Greiss Hess, L. et al. (2016): “A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome”. J Dev Behav Pediatr, 37 (8): 619-628.

Grigsby, J. (2016): “The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology”. Clin Neuropsychol, 30 (6): 815-833.

Hagerman, R. J. et al. (2014): “Translating molecular advances in fragile X syndrome into therapy: a review”. J Clin Psychiatry, 75 (4): e294-307.

Hagerman, R. J. (2006): “Lessons from fragile X regarding neurobiology, autism, and neurodegeneration”. J Dev Behav Pediatr, 27 (1): 63-74.

Hagerman, R. J. y Hagerman, P. J. (2002): Fragile X syndrome. 3er ed. Baltimore: The Johns Hopkins University Press.

Hanson, A. C y Hagerman, R. J. (2014): “Serotonin dysregulation in Fragile X Syndrome: implications for treatment”. Intractable Rare Dis Res, 3 (4): 110-117.

He, C. X. y Portera-Cailliau, C. (2013): “The trouble with spines in fragile X syndrome: density, maturity and plasticity”. Neuroscience, 251: 120-128.

Iossifov, I. et al. (2012): “De novo gene disruptions in children on the autistic spectrum”. Neuron, 74 (2): 285-299.

Jacquemont, S. et al. (2011): “Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056”. Sci Transl Med, 3 (64): 64ra1.

Leigh, M. J. et al. (2013): “A randomized double-blind placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome”. J Dev Behav Pediatr, 34 (3): 147- 155.

Ligsay, A. y Hagerman, R. J. (2016): “Review of targeted treatments in fragile X syndrome”. Intractable Rare Dis Res, 5 (3): 158-167.

Lima-Cabello, E. et al. (2016): “An Abnormal Nitric Oxide Metabolism Contributes to Brain Oxidative Stress in the Mouse Model for the Fragile X Syndrome, a Possible Role in Intellectual Disability”. Oxid Med Cell Longev, 2016.

Paribello, C. et al. (2010): “Open-label add-on treatment trial of minocycline in fragile X syndrome”. BMC Neuron, 10: 91.

Restivo, L. et al. (2005): “Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome”. Proc Natl Acad Sci U S A, 102 (32): 11557-11562.

Romero-Zerbo, Y. et al. (2009): “Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome”. J Pineal Res, 46 (2): 224-234.

Saldarriaga, W. et al. (2014): “Fragile X síndrome”. Colomb Med (Cali), 45 (4): 190-198.

Sahu, J. K. et al. (2013): “Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study”. J Child Neurol, 28 (5): 570-575.

Sidorov, M. S. et al. (2013): “Fragile X mental retardation protein and synaptic plasticity”. Mol Brain, 6: 15.

Tang, A. H. y Alger, B. E. (2015): “Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome”. J Neurosci. 35 (9): 3938-3945.

Tassone, F. et al. (2001): “A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA”. J Med Genet. 38 (7): 453-456.

Torrioli, M. G. et al. (2008): “A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys”. Am J Med Genet A, 146 (7): 803-812.

Utine, G. E. et al. (2014): “Neurochemical evaluation of brain function with 1H magnetic resonance spectroscopy in patients with fragile X syndrome”. Am J Med Genet A, 164A (1): 99-105.

Wirojanan, J. et al. (2009): “The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome”. J Clin Sleep Med, 5 (2): 145-150.